Recurrent IDH mutations in high-grade meningioma.
作者信息
Gill Corey M, Loewenstern Joshua, Rutland John W, Arib Hanane, Francoeur Nancy, Wang Ying-Chih, Fishman Nataly, Pain Margaret, Umphlett Melissa, Kinoshita Yayoi, McBride Russell B, Bederson Joshua, Donovan Michael, Smith Melissa, Sebra Robert, Shrivastava Raj K, Fowkes Mary
机构信息
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
Neuro Oncol. 2020 Jul 7;22(7):1044-1045. doi: 10.1093/neuonc/noaa065.
Abstract
摘要
相似文献
1
Recurrent IDH mutations in high-grade meningioma.
Neuro Oncol. 2020 Jul 7;22(7):1044-1045. doi: 10.1093/neuonc/noaa065.
2
Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
Brain Behav. 2020 Apr;10(4):e01583. doi: 10.1002/brb3.1583. Epub 2020 Mar 8.
3
Genomic profiling of anaplastic meningioma identifies recurrent genetic alterations with relevance to lower-grade meningioma.
Neuropathol Appl Neurobiol. 2019 Feb;45(2):179-182. doi: 10.1111/nan.12487. Epub 2018 May 8.
4
Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Chin Clin Oncol. 2017 Jun;6(3):33. doi: 10.21037/cco.2017.06.11.
5
Diffuse glioma - Rare homozygous IDH point mutation, is it an oncogenetic mechanism?
Neuropathology. 2017 Dec;37(6):582-585. doi: 10.1111/neup.12401. Epub 2017 Aug 7.
6
IDH mutations in glioma and acute myeloid leukemia.
Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5.
7
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.
8
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Crit Rev Oncol Hematol. 2017 Dec;120:1-9. doi: 10.1016/j.critrevonc.2017.09.013. Epub 2017 Oct 3.
9
An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
J Clin Neurosci. 2016 Sep;31:56-62. doi: 10.1016/j.jocn.2015.11.030. Epub 2016 Jul 9.
10
Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.
Eur Radiol. 2016 Jun;26(6):1705-15. doi: 10.1007/s00330-015-4025-4. Epub 2015 Sep 22.
引用本文的文献
1
Rapid diagnosis of adult-type diffuse glioma using a layered scheme.
BMC Med. 2025 Jun 2;23(1):325. doi: 10.1186/s12916-025-04124-9.
2
mutation associated with accelerated time to recurrence for older patients with atypical meningiomas.
Br J Neurosurg. 2025 Apr;39(2):173-179. doi: 10.1080/02688697.2023.2204927. Epub 2023 Apr 25.
3
Association between tumor mutations and meningioma recurrence in Grade I/II disease.
Oncoscience. 2022 Dec 9;9:70-81. doi: 10.18632/oncoscience.570. eCollection 2022.
4
NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
J Neurooncol. 2023 Jan;161(2):309-316. doi: 10.1007/s11060-022-04197-z. Epub 2022 Nov 27.
5
ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas.
J Cancer Res Clin Oncol. 2023 Jul;149(8):5165-5172. doi: 10.1007/s00432-022-04442-y. Epub 2022 Nov 9.
6
Progestin-related WHO grade II meningiomas behavior-a single-institution comparative case series.
Neurosurg Rev. 2022 Apr;45(2):1691-1699. doi: 10.1007/s10143-021-01708-w. Epub 2021 Nov 30.
7
SWI/SNF chromatin remodeling complex alterations in meningioma.
J Cancer Res Clin Oncol. 2021 Nov;147(11):3431-3440. doi: 10.1007/s00432-021-03586-7. Epub 2021 Mar 14.
8
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Acta Neuropathol Commun. 2020 Oct 21;8(1):171. doi: 10.1186/s40478-020-01040-2.
9
NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas.
Cancer Immunol Immunother. 2021 Jan;70(1):169-176. doi: 10.1007/s00262-020-02671-z. Epub 2020 Jul 13.
本文引用的文献
1
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131.
2
Treatment-associated DNA-binding domain missense mutations in the pathogenesis of secondary gliosarcoma.
Oncotarget. 2017 Dec 20;9(2):2603-2621. doi: 10.18632/oncotarget.23517. eCollection 2018 Jan 5.
3
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
4
The 2007 WHO classification of tumours of the central nervous system.
Acta Neuropathol. 2007 Aug;114(2):97-109. doi: 10.1007/s00401-007-0243-4. Epub 2007 Jul 6.
Zotero 插件